News & Articles

The Direct assay is validated on a wide range of specimen types, and can be run in parallel with the Simplexa Flu A/B & RSV Direct Gen II assay

cPass is first commercially available product to rapidly detect neutralizing antibodies capable of eliminating virus

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus

The collaboration aims to define threshold for neutralizing antibody sufficient to confer immunity

Access Anti-SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, aims to provide accurate results in less than 15 minutes

New dye offers researchers improved brightness to resolve rare and low antigen density populations more easily

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions

Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%

First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combination

Workflow is quick, simple and scalable for high-throughput antibody detection with high PPA sensitivity and NPA specificity

Supports cross-functional teams of chemists and biologists developing non-natural, chemically modified therapeutics for drug discovery

A Cambridge-developed vaccine candidate against SARS-CoV-2 could begin clinical trials in the UK as early as autumn, thanks to a £1.9million award from the UK government

The overall goal is to continue to detect and discover critical components in the overall cellular response to COVID-19

Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season

Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies

Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.

It is the first and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology

IgM assay has 95.51% positive predictive value even when disease incidence is only 3%

Used to empower clinicians to quickly prescribe treatment regimens for multidrug-resistant TB, the test could help fill a critical gap that is jeopardizing global TB targets

Leveraging GenMark’s eSensor XT-8 platform hopes to expand COVID-19 diagnostic testing capacity